WO2010150245A1 - Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts - Google Patents
Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts Download PDFInfo
- Publication number
- WO2010150245A1 WO2010150245A1 PCT/IL2010/000486 IL2010000486W WO2010150245A1 WO 2010150245 A1 WO2010150245 A1 WO 2010150245A1 IL 2010000486 W IL2010000486 W IL 2010000486W WO 2010150245 A1 WO2010150245 A1 WO 2010150245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cannabis
- composition
- ointment
- condition
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 240000004308 marijuana Species 0.000 title claims description 11
- 239000002537 cosmetic Substances 0.000 title 1
- 241000218236 Cannabis Species 0.000 claims abstract description 129
- 206010061218 Inflammation Diseases 0.000 claims abstract description 19
- 230000004054 inflammatory process Effects 0.000 claims abstract description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 77
- 239000002674 ointment Substances 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 244000025254 Cannabis sativa Species 0.000 claims description 29
- 235000008697 Cannabis sativa Nutrition 0.000 claims description 29
- 241000196324 Embryophyta Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000005607 chanvre indien Nutrition 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 8
- 241001083505 Punica Species 0.000 claims description 8
- 235000014360 Punica granatum Nutrition 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 241000219991 Lythraceae Species 0.000 claims description 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 241000209140 Triticum Species 0.000 claims description 6
- 235000021307 Triticum Nutrition 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 4
- 229960002733 gamolenic acid Drugs 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 3
- 229930003827 cannabinoid Natural products 0.000 description 21
- 239000003557 cannabinoid Substances 0.000 description 21
- 229940065144 cannabinoids Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 8
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 7
- 229960004242 dronabinol Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 4
- 229950011318 cannabidiol Drugs 0.000 description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013525 pomegranate juice Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- -1 THC Natural products 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 2
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical class C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- This invention relates to preparations with anti-inflammatory properties, hi particular, those preparations containing as active ingredients extracts of flowers and seeds of Cannabis sp.
- cannabinoids The anti-inflammatory properties of cannabinoids are well-known (Mechoulam, R. "Alkaloids in Cannabis sativa L.”; In: The Alkaloids; Brossi, A, Ed.; San Diego: Academic Press, 1988, 77-93). Indeed, cannabis has been a component of traditional folk remedies, in particular for skin conditions, in many cultures (see, for example * Oumeish, O. Y., "Traditional Arabic Medicine in Dermatology,” Clinics in Dermatology 1999, 17, 13-20, and Mamedov, N.; Gardner, Z.; Craker, L. E., "Medicinal Plants Used in Russia and Central Asia for the Treament of Skin Conditions," J. Herbs, Spices, Med. Plants 2005, 11, 191- 222).
- Patent Application 11/327,693 discloses the use of cannabinol derivatives for treatment inter alia of diseases which are the result of inflammation such as Crohn's disease, ulcerative colitis, and some forms of asthma.
- U.S. Patent Application 11/115,983 discloses a combination of THC and CBD for use to alleviate pain associated with cancer. More relevant to the present invention, a number of inventions have been disclosed that include cannabinoids as therapeutic agents for treatment of skin conditions, or that disclose dermal or transdermal delivery methods for cannabinoids.
- PCT Application WO2007/001891 discloses a composition in which a cannabinoid is combined with a permeation enhancer for improved transdermal delivery of the cannabinoid
- PCT Application WO2008/024408 discloses a composition for transdermal delivery of a cannabinoid that reduces the likelihood of the patient's using the cannabinoid as a drug of abuse.
- a cannabinoid is used in combination with another therapeutic agent.
- U.S. Patent Application 11/510,390 discloses a combination therapy in which a cannabinoid receptor agonist (e.g. THC) is combined with a cannabinoid receptor antagonist that serves to potentiate the activity of the cannabinoid receptor agonist.
- compositions including inter alia compositions containing a cannabinoid and a long-chain unsaturated fatty acid, for treatment of immunoproliferative skin disorders such as psoriasis.
- compositions have in common that they comprise a limited set of specific compounds.
- the cannabinoids in these compounds are either extracted and purified from Cannabis sp., or are synthetic derivatives or analogs of naturally-occurring cannabinoids. It is known, however, that the pharmaceutical activity of cannabis extract is different than that of pure cannabinoids such as THC, and the possibility of synergistic effects among the components of cannabis extract has been hypothesized (Ben-Shabat, S; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M. H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzio, V.; Mechoulam, R.
- the invention disclosed herein comprises a mixture of extracts from flowers and seeds of Cannabis sp.
- the anti-inflammatory properties of these extracts is used to produce an all- natural composition that is effective against conditions, particularly skin conditions, that are characterized by inflammation of tissues.
- the particular combination of these two extracts has a synergistic effect over either extract used alone.
- the composition can also be incorporated into an ointment for dermal or transdermal application of the composition. It is therefore an object of the invention to disclose a composition for treating a condition, said composition adapted for application to the skin and said condition characterized by inflammation of tissue, wherein said composition comprises a mixture of cannabis flower extract and cannabis seed extract.
- composition wherein said cannabis flower extract is obtained by extraction of dried flowers of Cannabis sp. by ethanol. It is a further object of this invention to disclose such a composition, wherein said cannabis flower extract is obtained from a hybrid plant of Cannabis indica and Cannabis sativa. It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
- Cannabis sativa is a genotype the seeds of which have a high gamma linolenic acid content.
- composition comprises said cannabis flower extract and said base in a ratio of about 5:95.
- transdermal ointment for treating a condition characterized by inflammation of tissue, wherein said transdermal ointment comprises a composition according to claim 1 compounded with a vehicle.
- step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers with ethanol.
- step of obtaining cannabis flower extract further includes the additional step of obtaining dried flowers of Cannabis sp. It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers obtained from a hybrid plant of Cannabis indica and Cannabis sativa.
- step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds using supercritical CO 2 .
- step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds by cold pressing.
- step of obtaining cannabis seed extract further comprises the additional steps of (a) obtaining seeds of Cannabis sativa; and (b) producing an extract from said seeds.
- step of obtaining seeds of Cannabis sativa further comprises the additional step of obtaining seeds from a genotype of Cannabis sativa the seeds of which have a high gamma linolenic acid content.
- step of obtaining cannabis seed extract further comprises the additional step of preparing a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about
- step of mixing said cannabis flower extract and said cannabis seed extract further includes the additional step of mixing said cannabis flower extract and said base in a ratio of about 5:95.
- cannabis flowers and “cannabis seed” as used herein refer to the flowers and seeds of any species of plant in the genus Cannabis.
- the terms “extraction,” and “extracting” refer to any process known in the art by which soluble components of plant material are separated from the plant by dissolving them in a solvent, and the term “extract” refers to any solution thus obtained.
- the terms as used herein do not imply any restriction or limitation on the details of the process or the specific content of the extract thus produced.
- the term “DMSO” refers to the chemical dimethylsulfoxide.
- the basic composition disclosed in the present invention comprises two components, an extract of cannabis flowers (Cannabis Flos) and an extract of cannabis seed (Cannabis Semen). The details of the extraction processes are well-known to those skilled in the art.
- the general methods by which the extracts are obtained in the preferred embodiments are as follows.
- the cannabis flower extract is obtained by ethanol extraction of cannabis flowers.
- the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice (i.e. the juice of the fruit of Punica grantwn).
- the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice obtained from organically grown of dried flowers of Cannabis sp.
- the cannabis seed extract is obtained by cold- pressing.
- the cannabis seed extract is obtained by supercritical fluid extraction using CO 2 as the solvent.
- the cannabis flower extract is obtained from a hybrid plant of about 80% Cannabis indica and about 20% Cannabis sativa.
- the hybrid plants from the which extracts are prepared are organically grown.
- the cannabis seed extract is obtained from seeds of Cannabis sativa.
- the cannabis plants from which the seed extract is obtained are organically grown Cannabis sativa.
- the organically grown Cannabis sativa from which the seed extract is prepared is a genotype with a high concentration of gamma linolenic acid (GLA) in its oil.
- GLA gamma linolenic acid
- This genotype is preferred because these seeds provide a stronger synergistic effect when their extract is combined with cannabis flower extract.
- the exact origin of this synergistic effect remains obscure; it appears to originate from the unexpected benefit of the combined action of THC found in cannabis flower extract with at least one of the literally dozens of natural products (e.g. other cannabinoids, terpenoids, fatty acids, sterols, etc.) found in cannabis seed extract.
- the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 1:99 and about 99:1. In a more preferred embodiment of the invention, the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 5:95 and about 20:80. In a most preferred embodiment of the invention, the cannabis seed extract is provided as a base comprising about 10% pomegranate seed oil, about 5% wheat kernel oil, and about 85% cannabis seed extract, -and the ratio of cannabis flower extract to the base containing cannabis seed extract is about 5:95.
- the composition is compounded with an appropriate vehicle in order to produce a transdermal ointment for direct application to the skin.
- the vehicle is Cera Alba (white beeswax).
- the ointment comprises between about 5% and about 15% of the composition described above. In a preferred embodiment of the invention, the ointment comprises between about 8% and about 12% of the composition described above. In a most preferred embodiment of the invention, the ointment comprises about 9% of the composition described above.
- the ointment further comprises DMSO.
- the DMSO is added in order to facilitate transdermal penetration of the composition into subdermal tissues.
- the ointment comprises between about 1% and about 25% DMSO.
- the ointment comprises between about 5% and about 15% DMSO.
- the ointment comprises about 10% DMSO.
- the composition is provided in a form adapted for other parenteral uses including, as non-limiting examples, intravenous, nasopharyngeal, and inhalation.
- composition and ointment described above are designed to treat, lessen the effects of, and/or palliate the symptoms of a number of conditions characterized by inflammation of tissues. As described in detail in the examples presented below, these conditions include, but are by no means limited to, psoriasis, psoriatic arthritis, atopic dermatitis, and rheumatoid arthritis.
- the present invention also provides a method for preparing a composition for the treatment of a condition characterized by inflammation of tissues.
- the method comprises the steps of (a) obtaining cannabis flower extract; (b) obtaining cannabis seed extract; and (c) mixing said cannabis flower extract and said cannabis seed extract in a predetermined ratio until a homogeneous composition is obtained.
- This general method will produce any of the embodiments of the composition described above, according to the ratio of the two extracts, the specific cannabis plants, and specific extraction method used.
- the present invention also provides a method for preparing a transdermal ointment for the treatment of a condition characterized by inflammation of tissues.
- the method comprises the steps of (a) obtaining a composition for treatment of a condition characterized by inflammation of tissues as defined above and (b) compounding a said composition with a vehicle in a predetermined ratio until a homogeneous ointment is obtained.
- An additional embodiment of the method includes the step of adding a predetermined quantity of DMSO to the vehicle in order to prepare a transdermal ointment with increased ability to penetrate to subdermal tissues.
- Cannabis flower extract as used in the invention herein disclosed.
- Flowers of the Erez hybrid of Cannabis indica / Cannabis sativa were carefully picked at maturity and manually trimmed with steel scissors to remove leaves.
- the flowers were then immediately placed in an opaque plain brown paper bag and wrapped up by the bag's own paper body.
- the wrapped bag was then left in a room at ambient temperature for at least two weeks and most preferably for three weeks at which time the flowers have surrendered over 80% of their fresh weight as humidity and are quite dry to the touch.
- the whole completely dry trimmed flowers are then weighed and 40 grams of material are placed in a dry, clean 500 ml glass bottle. This requires some little nudging but does not require outright pressing or crushing.
- Nonsteroidal anti-inflammatory drugs provided orally and topically in an ointment had afforded moderate relief for a couple of hours after each use, with gradual return of the pain.
- the patient then began a course of treatment with the ointment disclosed herein in place of the NSAIDs.
- the patient applied a small amount (-0.3 ml) of the ointment topically to the hip and massaged it in.
- the treatment was repeated on several occasions over the course of a week.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21979009P | 2009-06-24 | 2009-06-24 | |
| US61/219,790 | 2009-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010150245A1 true WO2010150245A1 (en) | 2010-12-29 |
Family
ID=43386085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL2010/000486 WO2010150245A1 (en) | 2009-06-24 | 2010-06-21 | Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010150245A1 (ko) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| WO2018006165A1 (en) * | 2016-07-03 | 2018-01-11 | 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. | Cannabis compositions and methods |
| US10058531B1 (en) | 2017-06-01 | 2018-08-28 | Spartak LLC | Dosage delivery film |
| US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| IT201800020590A1 (it) | 2018-12-20 | 2020-06-20 | Arterra Bioscience S P A | Uso cosmetico, farmaceutico e nutraceutico di un estratto derivato da colture cellulari di Cannabis sativa |
| WO2020129043A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis sativa lines and extracts with anti-cancer properties |
| WO2020129045A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts for treating skin disorders |
| WO2020129044A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts for skin rejuvenation and skin protection |
| WO2020129046A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts with anti-inflammatory potencies |
| US12102656B2 (en) | 2018-10-22 | 2024-10-01 | Dona J Llc | Topical compositions incorporating cannabis |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
| US20030017216A1 (en) * | 2001-07-23 | 2003-01-23 | Schmidt Robert Gustav | Isolation of herbal and cannabinoid medicinal extracts |
| US20040049059A1 (en) * | 2000-10-17 | 2004-03-11 | Adam Mueller | Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts |
| US20060068034A1 (en) * | 2002-08-14 | 2006-03-30 | Brian Whittle | Pharmaceutical formulation |
| US20070032544A1 (en) * | 2004-02-02 | 2007-02-08 | Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno | Medicinal acidic cannabinoids |
| US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
| WO2008007123A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2009039843A2 (de) * | 2007-09-26 | 2009-04-02 | Letzel Heinz | Pflanzenextrakt aus thc-armen cannabis zur behandlung von erkrankungen |
| US20090258098A1 (en) * | 2008-04-15 | 2009-10-15 | Lane Rolling | Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections |
| US20100080861A1 (en) * | 2008-09-05 | 2010-04-01 | Lvmh Recherche | Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin |
| US20100166891A1 (en) * | 2008-12-23 | 2010-07-01 | Intendis Gmbh | Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome |
| US20100233128A1 (en) * | 2009-03-13 | 2010-09-16 | Mci Media Capital Inc. | Natural Skin Products Containing Dairy and Processes |
-
2010
- 2010-06-21 WO PCT/IL2010/000486 patent/WO2010150245A1/en active Application Filing
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
| US20040049059A1 (en) * | 2000-10-17 | 2004-03-11 | Adam Mueller | Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts |
| US20030017216A1 (en) * | 2001-07-23 | 2003-01-23 | Schmidt Robert Gustav | Isolation of herbal and cannabinoid medicinal extracts |
| US20060068034A1 (en) * | 2002-08-14 | 2006-03-30 | Brian Whittle | Pharmaceutical formulation |
| US20070032544A1 (en) * | 2004-02-02 | 2007-02-08 | Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno | Medicinal acidic cannabinoids |
| US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
| WO2008007123A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2009039843A2 (de) * | 2007-09-26 | 2009-04-02 | Letzel Heinz | Pflanzenextrakt aus thc-armen cannabis zur behandlung von erkrankungen |
| US20090258098A1 (en) * | 2008-04-15 | 2009-10-15 | Lane Rolling | Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections |
| US20100080861A1 (en) * | 2008-09-05 | 2010-04-01 | Lvmh Recherche | Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin |
| US20100166891A1 (en) * | 2008-12-23 | 2010-07-01 | Intendis Gmbh | Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome |
| US20100233128A1 (en) * | 2009-03-13 | 2010-09-16 | Mci Media Capital Inc. | Natural Skin Products Containing Dairy and Processes |
Non-Patent Citations (7)
| Title |
|---|
| BLAKE ET AL.: "Preliminary assessment of the efficacy, tolerability and safety of a cannabis- based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.", RHEUMATOLOGY, vol. 45, no. 1, 9 November 2005 (2005-11-09), pages 50 - 52, Retrieved from the Internet <URL:http://rheumatology.oxfordjournals.org/content/45/1.toc> [retrieved on 20101019] * |
| KLEIN: "Cannabinoid-Based Drugs as Anti-Inflammatory Therpaeutics.", NATURE REVIEWS IMMUNOLOGY, vol. 5, no. 5, May 2005 (2005-05-01), pages 400 - 411, Retrieved from the Internet <URL:http://www.nature.com/nri/index.html> [retrieved on 20101019] * |
| KUPCYK ET AL.: "Cannabinoid system in the skin - a possible target for future therapies in dermatology.", EXPERIMENTAL DERMATOLOGY, vol. 18, no. 8, 24 June 2009 (2009-06-24), pages 669 - 679, Retrieved from the Internet <URL:http://www.wiley.com/bw/journal.asp?ref=0906-6705> [retrieved on 20101019] * |
| WARE ET AL.: "The medicinal use of cannabis in the UK: results of a nationwide survey.", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol. 59, no. 3, March 2005 (2005-03-01), pages 291 - 295, Retrieved from the Internet <URL:http://www.blackwellpublishing.com/ijcp_enhanced> [retrieved on 20101019] * |
| WHITTLE ET AL.: "Prospects for New Cannabis-Based Prescription Medicines.", JOURNAL OF CANNABIS THERAPEUTICS, vol. 1, no. 3, June 2001 (2001-06-01), pages 183 - 205, Retrieved from the Internet <URL:http://www.cannabis-med.org/data/pdf/2001-03-04-11.pdf> [retrieved on 20101019] * |
| WILKINSON ET AL.: "Cannabinoids inhibit human keratinocyte proliferation through a non- CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 45, no. 2, February 2007 (2007-02-01), pages 87 - 92, XP005836247, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/joumal/09231811> [retrieved on 20101019], DOI: doi:10.1016/j.jdermsci.2006.10.009 * |
| WRIGHT ET AL.: "The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.", RHEUMATOLOGY, vol. 45, no. 6, June 2006 (2006-06-01), pages 781, Retrieved from the Internet <URL:http://rheumatology.oxfordjournals.org/content/45/6/781.1> [retrieved on 20101019] * |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11844763B2 (en) | 2014-04-17 | 2023-12-19 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
| US11478520B2 (en) | 2014-04-17 | 2022-10-25 | Cure Pharmaceutical Holding Corp | Pharmaceutical composition and method of manufacturing |
| US9980996B2 (en) | 2014-04-17 | 2018-05-29 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US11938160B2 (en) | 2014-04-17 | 2024-03-26 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
| US11331358B2 (en) | 2014-04-17 | 2022-05-17 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
| US10238705B2 (en) | 2014-04-17 | 2019-03-26 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
| US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US11344591B2 (en) | 2014-04-17 | 2022-05-31 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
| US11890310B2 (en) | 2014-04-17 | 2024-02-06 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
| US11266702B2 (en) | 2014-04-17 | 2022-03-08 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
| US11304393B2 (en) | 2016-05-27 | 2022-04-19 | New West Genetics Inc. | Industrial hemp cannabis cultivars and seeds with stable cannabinoid profiles |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| US10537592B2 (en) | 2016-06-29 | 2020-01-21 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| US10383892B2 (en) | 2016-06-29 | 2019-08-20 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| WO2018006165A1 (en) * | 2016-07-03 | 2018-01-11 | 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. | Cannabis compositions and methods |
| US10765713B2 (en) | 2016-07-03 | 2020-09-08 | 3277991 Nova Scotia Limited | Cannabis compositions and methods |
| US10307394B2 (en) | 2017-06-01 | 2019-06-04 | Spartak LLC | Dosage delivery film |
| US10857125B2 (en) | 2017-06-01 | 2020-12-08 | Spartak LLC | Dosage delivery film |
| US10058531B1 (en) | 2017-06-01 | 2018-08-28 | Spartak LLC | Dosage delivery film |
| US12029722B2 (en) | 2017-06-01 | 2024-07-09 | Spartak LLC | Dosage delivery film |
| US12102656B2 (en) | 2018-10-22 | 2024-10-01 | Dona J Llc | Topical compositions incorporating cannabis |
| WO2020129046A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts with anti-inflammatory potencies |
| WO2020129044A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts for skin rejuvenation and skin protection |
| WO2020129045A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis lines and extracts for treating skin disorders |
| WO2020129043A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis sativa lines and extracts with anti-cancer properties |
| WO2020127056A1 (en) | 2018-12-20 | 2020-06-25 | Arterra Bioscience S.P.A. | Cosmetic, pharmaceutical and nutraceutical use of an extract derived from cannabis sativa cell cultures |
| IT201800020590A1 (it) | 2018-12-20 | 2020-06-20 | Arterra Bioscience S P A | Uso cosmetico, farmaceutico e nutraceutico di un estratto derivato da colture cellulari di Cannabis sativa |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010150245A1 (en) | Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts | |
| EP2345416B1 (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| ITRM20080615A1 (it) | Fitocomplesso da frutto di bergamotto, procedimento di preparazione e impiego quale integratore alimentare e nel settore farmaceutico. | |
| KR101902911B1 (ko) | 산수국 추출물을 함유하는 자외선에 의한 인간 피부세포 손상 개선용 조성물 | |
| HK1049287A1 (en) | Topical application containing anemonin as effective component for treating aseptic inflammation and manufacturing method thereof | |
| CN107411987B (zh) | 一种面部清痘复方精油及其制备方法 | |
| KR100999870B1 (ko) | 어성초 및 느릅나무 혼합추출물을 유효 성분으로 함유하는알레르기성 피부질환 예방 및 치료용 약학적 조성물 | |
| US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
| KR101009904B1 (ko) | 천연 식물 추출물을 포함하는 항염 조성물 | |
| KR101033921B1 (ko) | 피부 염증 및 자극 완화 효과를 갖는 조성물 | |
| KR100991399B1 (ko) | 어성초, 금전초, 차전초, 느릅나무 및 상엽 혼합추출물을유효 성분으로 함유하는 알레르기성 피부질환 예방 및치료용 약학적 조성물 | |
| CN108813465A (zh) | 一种无花果功能咀嚼片及其制备方法 | |
| CN105748545B (zh) | 一种三七根转化皂苷在制备抗真菌絮状表皮癣菌、红色毛癣菌、须毛癣菌药物方面的应用 | |
| CN110227056A (zh) | 一种蜂胶口腔清新剂及其制备方法 | |
| Nge et al. | The polyphenolics and health effects of pomegranate | |
| KR101382137B1 (ko) | 히어리 및 얼레지의 혼합 추출물을 포함하는 조성물 | |
| Kumar et al. | Pharmacognostical, Pharmacological Studies and Traditional uses of Plectranthus Ambonicus: A Review | |
| CN104524519A (zh) | 一种感冒初期患者适用的特种纸手帕 | |
| Joshua | Phytochemical Constituents of Rosmarinus officinalis Linn. and Their Associated Role in the Management of Alzheimer’s Disease | |
| CN104127356A (zh) | 一种沙棘口咽抗菌消炎组合液及其制备方法 | |
| KR101093731B1 (ko) | 맥문동추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
| KR20120090123A (ko) | 여성의 생리통 완화용 피부도포형 필름형성제 조성물 및 이의 제조방법 | |
| CN109432290B (zh) | 一种具有皮肤抗敏功效的中药组合物及其水提物和发酵物与应用 | |
| Duran | Obtain Cucurbitacin from Ecballium elaterium and Cucurbita pepo and Converting into a Pharmaceutical Form | |
| Nwachuku et al. | Pomegranate seed extract: A strong antioxidant against benign prostatic hyperplasia induced oxidative stress in albino Wistar rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10791732 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 11.05.2012) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10791732 Country of ref document: EP Kind code of ref document: A1 |